Kassandra L Munger1, Kira Hongell2, Julia Åivo2, Merja Soilu-Hänninen2, Heljä-Marja Surcel2, Alberto Ascherio2. 1. From the Departments of Nutrition (K.L.M., A.A.) and Epidemiology (A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; Division of Clinical Neurosciences (K.H., J.Å., M.S.-H.), Turku University Hospital and University of Turku; and National Institute for Health and Welfare (H.-M.S.), Oulu, Finland. kgorham@hsph.harvard.edu. 2. From the Departments of Nutrition (K.L.M., A.A.) and Epidemiology (A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; Division of Clinical Neurosciences (K.H., J.Å., M.S.-H.), Turku University Hospital and University of Turku; and National Institute for Health and Welfare (H.-M.S.), Oulu, Finland.
Abstract
OBJECTIVE: To determine whether and to what extent vitamin D deficiency is associated with multiple sclerosis (MS) risk. METHODS: We conducted a prospective nested case-control study among women in the Finnish Maternity Cohort (FMC). The FMC had 1.8 million stored serum samples taken during the pregnancies of over 800,000 women at the time of this study. Through linkages with hospital and prescription registries, we identified 1,092 women with MS diagnosed between 1983 and 2009 with at least 1 serum sample collected prior to date of MS diagnosis; ≥2 serum samples were available for 511 cases. Cases were matched to up to 3 controls (n = 2,123) on date of birth (±2 years) and area of residence. 25-Hydroxyvitamin D (25[OH]D) levels were measured using a chemiluminescence assay. We used conditional logistic regression adjusted for year of sample collection, gravidity, and parity to estimate relative risks (RRs) and 95% confidence intervals (CIs). RESULTS: A 50 nmol/L increase in 25(OH)D was associated with a 39% reduced risk of MS (RR 0.61, 95% CI 0.44-0.85), p = 0.003. Women with 25(OH)D levels <30 nmol/L had a 43% higher MS risk (RR 1.43, 95% CI 1.02-1.99, p = 0.04) as compared to women with levels ≥50 nmol/L. In women with ≥2 samples, MS risk was 2-fold higher in women with 25(OH)D <30 nmol/L as compared to women with 25(OH)D ≥50 nmol/L (RR 2.02, 95% CI 1.18-3.45, p = 0.01). CONCLUSIONS: These results directly support vitamin D deficiency as a risk factor for MS and strengthen the rationale for broad public health interventions to improve vitamin D levels.
OBJECTIVE: To determine whether and to what extent vitamin D deficiency is associated with multiple sclerosis (MS) risk. METHODS: We conducted a prospective nested case-control study among women in the Finnish Maternity Cohort (FMC). The FMC had 1.8 million stored serum samples taken during the pregnancies of over 800,000 women at the time of this study. Through linkages with hospital and prescription registries, we identified 1,092 women with MS diagnosed between 1983 and 2009 with at least 1 serum sample collected prior to date of MS diagnosis; ≥2 serum samples were available for 511 cases. Cases were matched to up to 3 controls (n = 2,123) on date of birth (±2 years) and area of residence. 25-Hydroxyvitamin D (25[OH]D) levels were measured using a chemiluminescence assay. We used conditional logistic regression adjusted for year of sample collection, gravidity, and parity to estimate relative risks (RRs) and 95% confidence intervals (CIs). RESULTS: A 50 nmol/L increase in 25(OH)D was associated with a 39% reduced risk of MS (RR 0.61, 95% CI 0.44-0.85), p = 0.003. Women with 25(OH)D levels <30 nmol/L had a 43% higher MS risk (RR 1.43, 95% CI 1.02-1.99, p = 0.04) as compared to women with levels ≥50 nmol/L. In women with ≥2 samples, MS risk was 2-fold higher in women with 25(OH)D <30 nmol/L as compared to women with 25(OH)D ≥50 nmol/L (RR 2.02, 95% CI 1.18-3.45, p = 0.01). CONCLUSIONS: These results directly support vitamin D deficiency as a risk factor for MS and strengthen the rationale for broad public health interventions to improve vitamin D levels.
Authors: N Binkley; B Dawson-Hughes; R Durazo-Arvizu; M Thamm; L Tian; J M Merkel; J C Jones; G D Carter; C T Sempos Journal: J Steroid Biochem Mol Biol Date: 2016-12-12 Impact factor: 4.292
Authors: H T Viljakainen; E Saarnio; T Hytinantti; M Miettinen; H Surcel; O Mäkitie; S Andersson; K Laitinen; C Lamberg-Allardt Journal: J Clin Endocrinol Metab Date: 2010-02-05 Impact factor: 5.958
Authors: Nete Munk Nielsen; Kassandra L Munger; Nils Koch-Henriksen; David M Hougaard; Melinda Magyari; Kristian T Jørgensen; Marika Lundqvist; Jacob Simonsen; Tine Jess; Arieh Cohen; Egon Stenager; Alberto Ascherio Journal: Neurology Date: 2016-11-30 Impact factor: 9.910
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: Lauren E Mokry; Stephanie Ross; Omar S Ahmad; Vincenzo Forgetta; George Davey Smith; David Goltzman; Aaron Leong; Celia M T Greenwood; George Thanassoulis; J Brent Richards Journal: PLoS Med Date: 2015-08-25 Impact factor: 11.069
Authors: Kassandra L Munger; Kira Hongell; Marianna Cortese; Julia Åivo; Merja Soilu-Hänninen; Heljä-Marja Surcel; Alberto Ascherio Journal: Ann Neurol Date: 2019-07-03 Impact factor: 10.422
Authors: Kjetil Bjornevik; Kassandra L Munger; Marianna Cortese; Christian Barro; Brian C Healy; David W Niebuhr; Ann I Scher; Jens Kuhle; Alberto Ascherio Journal: JAMA Neurol Date: 2020-01-01 Impact factor: 18.302
Authors: Enrique González-Madrid; Ma Andreina Rangel-Ramírez; María José Mendoza-León; Oscar Álvarez-Mardones; Pablo A González; Alexis M Kalergis; Ma Cecilia Opazo; Claudia A Riedel Journal: Int J Mol Sci Date: 2022-06-25 Impact factor: 6.208
Authors: Steve Simpson; Ingrid van der Mei; Robyn M Lucas; Anne-Louise Ponsonby; Simon Broadley; Leigh Blizzard; Bruce Taylor Journal: Front Neurol Date: 2018-02-01 Impact factor: 4.003